DAX ®12.468,01+0,08%TecDAX ®2.868,59-0,88%Dow Jones26.935,07-0,59%NASDAQ 1007.823,55-0,99%
finanztreff.de

BUSINESS WIRE: Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics

| Quelle: Business_Wire | Lesedauer etwa 3 min. | Text vorlesen Stop Pause Fortsetzen

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

  • Boehringer Ingelheim has entered into a collaboration and global license agreement for Bridge Biotherapeutics’s autotaxin inhibitor BBT-877 to be developed for fibrosing interstitial lung diseases including IPF
  • With this new partnership Boehringer Ingelheim further expands its commitment to bring new treatments to patients with fibrosing interstitial lung diseases including IPF
  • Bridge Biotherapeutics stands to receive up to more than EUR 1.1 billion assuming all milestones are met

 

INGELHEIM, Germany & SEONGNAM, Korea (BUSINESS WIRE) 18.07.2019

Boehringer Ingelheim and Bridge Biotherapeutics Inc. today announced that they are entering into a new collaboration and license agreement with the goal of developing Bridge Biotherapeutics’s autotaxin inhibitor BBT-877 for patients with fibrosing interstitial lung diseases, including IPF. BBT-877 is currently in Phase I clinical studies and is anticipated to enter Phase II testing within the next 12 months.

Both companies will initially focus on developing the compound for the treatment of IPF, an area of high-unmet medical need and one of the key focus areas of Boehringer Ingelheim. Boehringer Ingelheim has developed OFEV® (nintedanib), an antifibrotic drug shown to slow disease progression by reducing lung function decline and currently approved for the treatment of IPF in more than 70 countries around the world including the US, the EU and Japan.

IPF is a rare, debilitating and fatal lung disease affecting approximately three million people worldwide. It causes progressive scarring of the lungs, resulting in continual and irreversible deterioration in lung function and breathing difficulties. BBT-877 inhibits autotaxin, an enzyme mediating a key pro-fibrotic event in multiple cell types. It has shown a promising safety and efficacy profile in pre-clinical models for fibrosing interstitial lung diseases and potential for combination with the current standard of care.

Michel Pairet, member of Boehringer Ingelheim’s Board of Managing Directors with responsibility for the company’s Innovation Unit said, “We look forward to working with the team at Bridge Biotherapeutics to develop a new treatment option for patients with IPF. This new collaboration complements our growing pipeline in fibrosing interstitial lung diseases and is a sign of our determination to bring the next generation of treatment options to these patients.”

“Bridge Biotherapeutics is pleased to partner with Boehringer Ingelheim, a recognized leader in IPF. The expertise of Boehringer Ingelheim will ensure that our novel therapeutic candidate can be developed to potentially address unmet medical needs of IPF patients worldwide,” said James Lee, CEO of Bridge Biotherapeutics.

“This is a transformational event for Bridge Biotherapeutics with a total potential value in excess of EUR 1.1 billion. It is a testament to the company’s excellence in the development of novel therapeutics for disease areas with high unmet medical need,” commented B. Chris Kim, PhD, a board member of Bridge Biotherapeutics based in Cambridge, Massachusetts.

Bridge Biotherapeutics will receive upfront and near term payments of EUR 45 million and is eligible to receive up to more than EUR 1.1billion in potential payments based upon the successful achievement of specified development, regulatory, and commercial milestones and staggered, up to double digit royalties.

Please click on the link for Notes to Editors:
http://www.boehringer-ingelheim.com/press-release/collaboration-bridge-biotherapeutics

Media Contacts
Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
reinhard.malin@boehringer-ingelheim.com

Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: + 203-791-6672
linda.ruckel@boehringer-ingelheim.com

Bridge Biotherapeutics, Inc.
Joengbin Ahn
Communications Manager
+82 10-6257-3517
Joengbin.Ahn@bridgebiorx.com

Werbung

Das könnte Sie auch interessieren

Weitere Nachrichten

Quelle: Business_Wire
20.09. BUSINESS WIRE: Toshiba Memory Holdings Corporation ernennt Lorenzo A. Flores zum stellvertretenden Vorstandsvorsitzenden
20.09. BUSINESS WIRE:  Ipsen to Present New Data at 13th Annual Conference of the International Liver Cancer Association (ILCA 2019) IPSEN S.A. PORT. EO 1 90,90 +1,00%
20.09. BUSINESS WIRE: Seoul Semiconductor: l’illuminazione degli uffici a prova di futuro incentrata sulle persone è già qui grazie a SunLike
20.09. BUSINESS WIRE: Seoul Semiconductor: Mit SunLike ist zukunftsfähige mitarbeiterorientierte Bürobeleuchtung bereits da
20.09. BUSINESS WIRE: Visa B2B Connect estende la propria presenza in altri 32 paesi e annuncia l’integrazione con Infosys
20.09. BUSINESS WIRE: Tag der offenen Tür bei ISAE-SUPAERO!
20.09. BUSINESS WIRE: Open Day nella sede dell'ISAE-SUPAERO!
20.09. BUSINESS WIRE: William Priest tritt 2020 als CEO zurück und gehört dem Unternehmen unverändert als Executive Chairman und Co-CIO an
20.09. BUSINESS WIRE: William Priest lascerà l'incarico nel 2020 ma resterà in azienda come Presidente Esecutivo e co-CIO
20.09. BUSINESS WIRE: RoboSense RS-LiDAR-M1 Smart LiDAR Sensor Wins AutoSens Awards 2019
Rubrik: Finanzmarkt
20.09. Britische Ryanair-Piloten sagen Streik ab RYANAIR HLDGS PLC EO-,006 9,92 +1,45%
20.09. Huthis wollen Angriffe auf Saudi-Arabien einstellen
20.09. ROUNDUP/Aktien New York Schluss: Handelsstreit sorgt wieder für Verluste Dow Jones 26.935,07 -0,59%
20.09. Aktien New York Schluss: Handelsstreit sorgt wieder für Verluste Dow Jones 26.935,07 -0,59%
20.09. DGAP-DD: De Raj Group AG (deutsch) DE RAJ GROUP AG INH O.N. 3,40 +6,25%
20.09. ANALYSE-FLASH: Commerzbank hebt RWE auf 'Buy' und Ziel auf 32 Euro RWE ST 28,32 +3,62%
20.09. US-Anleihen steigen weiter
20.09. Devisen: Euro bleibt in New York unter druck EUR/USD 1,1018 -0,2237%
20.09. BUSINESS WIRE: Toshiba Memory Holdings Corporation ernennt Lorenzo A. Flores zum stellvertretenden Vorstandsvorsitzenden
20.09. DGAP-News: Elmos Semiconductor AG unterzeichnet Vertrag zum Verkauf der Silicon Microstructures Inc. an TE Connectivity Ltd. (deutsch) ELMOS SEMICONDUCTOR AG 26,40 +4,35%
Werbung

News-Suche

Suchbegriff:
Werbung

Werbung
Diese Seite empfehlenschliessen
Interessant, oder?
Teilen Sie diese Seite auf Facebook oder Twitter
Wenn Sie auf die Teilen-Buttons klicken und sich bei den Betreibern einloggen, werden Daten an den jeweiligen Betreiber übermittelt. Bitte beachten Sie die Datenschutzerklärung.
Aktuelle Umfrageschliessen
Wie, glauben Sie, wird der DAX am Ende dieser Woche - KW 39 - stehen?
Jetzt abstimmen!
Alle Umfragen ansehen